8-K: Schrödinger Announces Q3 2024 Results and Landmark Novartis Collaboration

Schrödinger reported its third quarter 2024 financial results, highlighted by a new $150 million upfront collaboration with Novartis and updated full-year financial guidance.

Summary

• Schrödinger's total revenue for the third quarter of 2024 was $35.3 million, a decrease from $42.6 million in the same period of 2023.
• Software revenue increased by 10% to $31.9 million, up from $28.9 million in the third quarter of 2023, driven by hosted licenses.
• Drug discovery revenue significantly decreased to $3.4 million, compared to $13.7 million in the third quarter of 2023, due to the absence of accelerated revenue recognition from programs no longer in the collaborative portfolio.
• The company's software gross margin decreased to 73% from 76% in the prior year, due to lower profitability from the predictive toxicology initiative.
• Operating expenses rose to $86.2 million, compared to $79.8 million in the third quarter of 2023, primarily due to increased R&D spending.
• Other income was $30.2 million, compared to an expense of $8.7 million in the third quarter of 2023, mainly due to changes in the fair value of equity investments.
• Net loss for the quarter was $38.1 million, an improvement from a net loss of $62.0 million in the third quarter of 2023.
• Schrödinger had $398.4 million in cash, cash equivalents, restricted cash, and marketable securities as of September 30, 2024, down from $468.8 million at the end of 2023.
• The company updated its 2024 full-year financial guidance, expecting software revenue growth between 8% and 13% and drug discovery revenue between $20 million and $30 million.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the significant Novartis collaboration and increased software revenue, but tempered by the decrease in total revenue and drug discovery revenue, as well as the reduced cash balance.

Positives

• The collaboration with Novartis provides a significant upfront payment of $150 million and potential future milestone payments of up to $2.3 billion.
• Software revenue continues to grow, increasing by 10% year-over-year.
• The company's net loss decreased significantly compared to the same quarter last year.
• Schrödinger received a substantial cash infusion from the Morphic acquisition.
• The company is advancing its proprietary pipeline with multiple programs in clinical development.

Negatives

• Total revenue decreased by 17% compared to the third quarter of 2023.
• Drug discovery revenue decreased significantly by 75% year-over-year.
• Software gross margin decreased to 73% from 76% in the prior year.
• Operating expenses increased by 7.9% year-over-year.
• The company's cash balance decreased from the end of 2023.

Risks

• The company's reliance on third-party providers for cloud-based infrastructure could pose a risk.
• The success of the Novartis collaboration depends on Novartis's ability to develop and commercialize the discovered candidates.
• The company is subject to the uncertainties inherent in drug development and commercialization.
• There is a risk that results from preclinical studies may not be predictive of later clinical trials.
• The company's ability to retain and hire key personnel is crucial for its success.

Future Outlook

Schrödinger updated its 2024 full-year financial guidance, expecting software revenue growth between 8% and 13% and drug discovery revenue between $20 million and $30 million. The company also anticipates reporting initial clinical data from its lead programs in 2025.

Management Comments

• Ramy Farid, Ph.D., chief executive officer of Schrödinger, stated that recent progress, including the collaboration with Novartis, underscores the strength of their business model.
• Geoff Porges, MBBS, chief financial officer of Schrödinger, mentioned that they have increased the lower end of their software revenue growth guidance for the year, reflecting confidence in meeting growth goals.
• Geoff Porges also noted that collaborations continue to be an important element of their business model.

Industry Context

This announcement highlights the growing trend of pharmaceutical companies collaborating with technology-driven drug discovery platforms. The collaboration with Novartis underscores the value of computational methods in accelerating drug development. The increased software licensing agreement also reflects the industry's growing reliance on advanced computational tools.

Comparison to Industry Standards

• Schrödinger's 10% software revenue growth is a positive sign, but it is important to compare this to other computational drug discovery companies such as Recursion Pharmaceuticals (RXRX) and Exscientia (EXAI).
• The significant decrease in drug discovery revenue is concerning and should be compared to the performance of other companies with similar collaborative models, such as Relay Therapeutics (RLAY).
• The $150 million upfront payment from Novartis is a substantial deal, but the total potential value of $2.3 billion should be compared to other large pharma collaborations in the industry, such as those between BioNTech and Pfizer.
• The decrease in software gross margin to 73% should be compared to the gross margins of other software companies in the life sciences sector, such as Veeva Systems (VEEV).

Stakeholder Impact

• Shareholders will be impacted by the financial results and the potential of the Novartis collaboration.
• Employees may be affected by the company's financial performance and strategic direction.
• Customers will benefit from the continued development of Schrödinger's software platform.
• The collaboration with Novartis could lead to new therapies for patients.

Next Steps

• Schrödinger will continue to advance its proprietary pipeline programs.
• The company will focus on increasing software utilization among its customers.
• Schrödinger will report initial clinical data from its lead programs in 2025.
• The company will work with Novartis to advance multiple development candidates.

Key Dates

Keywords

Schrödinger, Novartis, Drug Discovery, Software, Collaboration, Financial Results, Computational Platform, Clinical Trials, Milestone Payments, Revenue